222 related articles for article (PubMed ID: 37720688)
61. Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis.
Franken A; Van Mol P; Vanmassenhove S; Donders E; Schepers R; Van Brussel T; Dooms C; Yserbyt J; De Crem N; Testelmans D; De Wever W; Nackaerts K; Vansteenkiste J; Vos R; Humblet-Baron S; Lambrechts D; Wauters E
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171010
[TBL] [Abstract][Full Text] [Related]
62. Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma.
Gaißler A; Bochem J; Spreuer J; Ottmann S; Martens A; Amaral T; Wagner NB; Claassen M; Meier F; Terheyden P; Garbe C; Eigentler T; Weide B; Pawelec G; Wistuba-Hamprecht K
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286306
[TBL] [Abstract][Full Text] [Related]
63. Efficacy of immune checkpoint inhibitor therapy in patients with
Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
[TBL] [Abstract][Full Text] [Related]
64. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
Brueckl WM; Ficker JH; Zeitler G
BMC Cancer; 2020 Dec; 20(1):1185. PubMed ID: 33272262
[TBL] [Abstract][Full Text] [Related]
65. Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors.
Bronte G; Verlicchi A; De Matteis S; Rossi A; Affatato A; Sullo FG; Gianni C; Canale M; Burgio MA; Delmonte A; Milella M; Crinò L
Front Immunol; 2021; 12():672219. PubMed ID: 34122429
[TBL] [Abstract][Full Text] [Related]
66. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Suzuki S; Haratani K; Hayashi H; Chiba Y; Tanizaki J; Kato R; Mitani S; Kawanaka Y; Kurosaki T; Hasegawa Y; Okabe T; Tanaka K; Akashi Y; Ozaki T; Nishio K; Ito A; Nakagawa K
Eur J Cancer; 2022 Jan; 161():44-54. PubMed ID: 34922263
[TBL] [Abstract][Full Text] [Related]
67. Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator.
Oliver L; Alvarez R; Diaz R; Valdés A; Colligan SH; Nemeth MJ; Twum DYF; Fernández A; Fernández-Medina O; Carlson LM; Yu H; Eng KH; Hensen ML; Rábade-Chediak ML; Fernández LE; Lee KP; Perez L; Muhitch JB; Mesa C; Abrams SI
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36150744
[TBL] [Abstract][Full Text] [Related]
68. Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma.
Xiang H; Ramil CP; Hai J; Zhang C; Wang H; Watkins AA; Afshar R; Georgiev P; Sze MA; Song XS; Curran PJ; Cheng M; Miller JR; Sun D; Loboda A; Jia Y; Moy LY; Chi A; Brandish PE
Cancer Immunol Res; 2020 Apr; 8(4):436-450. PubMed ID: 32075803
[TBL] [Abstract][Full Text] [Related]
69. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
70. LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs.
Su MT; Kumata S; Endo S; Okada Y; Takai T
Oncoimmunology; 2022; 11(1):2060907. PubMed ID: 35402083
[TBL] [Abstract][Full Text] [Related]
71. Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy.
Sarkar OS; Donninger H; Al Rayyan N; Chew LC; Stamp B; Zhang X; Whitt A; Li C; Hall M; Mitchell RA; Zippelius A; Eaton J; Chesney JA; Yaddanapudi K
Sci Adv; 2023 Jun; 9(26):eadg3736. PubMed ID: 37390211
[TBL] [Abstract][Full Text] [Related]
72. [The expression and association of CD14(+) HLA-DR(Low/-) myeloid-derived suppressor cell-like cells and interleukin-1β in ovarian cancer].
Wang HY; Zhao R; Ren H; Zou MJ; Zhang J; Zhang Y
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2663-2669. PubMed ID: 28910953
[No Abstract] [Full Text] [Related]
73. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
74. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
75. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
76. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
[TBL] [Abstract][Full Text] [Related]
77. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
[TBL] [Abstract][Full Text] [Related]
78. Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
Takeyama Y; Kato M; Tamada S; Azuma Y; Shimizu Y; Iguchi T; Yamasaki T; Gi M; Wanibuchi H; Nakatani T
Cancer Lett; 2020 Jun; 479():89-99. PubMed ID: 32200039
[TBL] [Abstract][Full Text] [Related]
79. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
Jordan KR; Kapoor P; Spongberg E; Tobin RP; Gao D; Borges VF; McCarter MD
Cancer Immunol Immunother; 2017 Apr; 66(4):503-513. PubMed ID: 28108766
[TBL] [Abstract][Full Text] [Related]
80. CCR2
Lebrun A; Lo Re S; Chantry M; Izquierdo Carerra X; Uwambayinema F; Ricci D; Devosse R; Ibouraadaten S; Brombin L; Palmai-Pallag M; Yakoub Y; Pasparakis M; Lison D; Huaux F
J Pathol; 2017 Nov; 243(3):320-330. PubMed ID: 28799208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]